sofidexFor patientsAre you a clinician? Clinical site
Ask Sofi
Listen
Patient SupportEmergencies & Reporting
Log inSign up

Meds & supplements  ›  Odesivimab

Medicine

Odesivimab

INMAZEB is indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection.

Prescribing label

Selected manufacturer label information, organised into consistent sections by Sofidex. This source is written for healthcare professionals; ask your pharmacist to explain instructions that are unclear. Read the full label at DailyMed ↗

Drug facts

Used for
  • INMAZEB is a combination of Orthoebolavirus zairense glycoprotein-directed human monoclonal antibodies (atoltivimab, maftivimab, and odesivimab), indicated for the treatment of infection caused by Orthoebolavirus zairense in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Orthoebolavirus zairense infection.
  • Orthoebolavirus zairense can change over time, and factors such as emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs.

Side effects, and when to stop

The following clinically significant adverse reactions are described elsewhere in the labeling:

  • Hypersensitivity Reactions Including Infusion-Associated Events

Who should not take it

None.

Storing it

Prior to dilution

Store INMAZEB vial refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton to protect from light. Do not freeze or shake.

After dilution

INMAZEB does not contain preservatives. It is always recommended to administer intravenous medication immediately after preparation when possible. Store the diluted INMAZEB solution as specified according to Table 12 below. Do not freeze the diluted solution.

Cite this page

NLM

sofidex [Internet]. Daloreum; c2026. Odesivimab; [reviewed 2026 Aug 3; cited 2026 Nov 10]. Available from: https://sofidex.com/patients/medicines/odesivimab

APA 7th

sofidex. (2026, August 3). Odesivimab. Daloreum. Retrieved November 10, 2026, from https://sofidex.com/patients/medicines/odesivimab

AMA 11th

Odesivimab. sofidex. Reviewed August 3, 2026. Accessed November 10, 2026. https://sofidex.com/patients/medicines/odesivimab

The cited date is today’s, because a citation records when you read the page. The reviewed date is when a clinician last checked it.